Kazuhiko Yamada

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 463 citations · Full text

Life Sciences, Immunology, Oncology +17

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science · 2018 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

Takaaki Tokito, Koichi Azuma, Akihiko Kawahara et al. · European Journal of Cancer · 2016 · 188 citations

Medicine, Clinical Sciences, Oncology +17

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara et al. · Journal of Thoracic Oncology · 2014 · 175 citations · Full text

Medicine, Cancer Biology, Oncology +14